Jay Olson
Stock Analyst at Oppenheimer
(3.87)
# 673
Out of 4,984 analysts
243
Total ratings
42.56%
Success rate
12.37%
Average return
Main Sectors:
Stocks Rated by Jay Olson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $44 | $6.91 | +536.76% | 4 | Aug 11, 2025 | |
| MNMD Mind Medicine (MindMed) | Reinstates: Outperform | $25 | $9.57 | +161.23% | 1 | Aug 4, 2025 | |
| ATAI Atai Life Sciences | Initiates: Outperform | $14 | $4.61 | +203.69% | 1 | Jul 29, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Outperform | $97 → $115 | $44.03 | +161.19% | 2 | Jul 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Perform | $19 → $22 | $24.20 | -9.09% | 15 | Jun 26, 2025 | |
| PRTA Prothena Corporation | Downgrades: Perform | n/a | $8.07 | - | 15 | May 27, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Outperform | $65 | $39.04 | +66.50% | 1 | May 21, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Outperform | $80 → $65 | $2.34 | +2,677.78% | 5 | May 15, 2025 | |
| INO Inovio Pharmaceuticals | Maintains: Outperform | $15 → $13 | $2.18 | +496.33% | 3 | May 14, 2025 | |
| RVMD Revolution Medicines | Maintains: Outperform | $70 → $75 | $43.81 | +71.19% | 9 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $21 | $8.07 | +160.22% | 2 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $90 | $51.06 | +76.28% | 6 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $42 | $13.06 | +221.59% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $41 → $33 | $40.44 | -18.40% | 6 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $40 | $12.41 | +222.32% | 9 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $20 | $1.79 | +1,017.32% | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $6.15 | +387.80% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $20 | $7.40 | +170.27% | 2 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $255 | $144.87 | +76.02% | 25 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $82 | $84.80 | -3.30% | 14 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $375 → $350 | $417.74 | -16.22% | 10 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $10 | $2.86 | +249.55% | 4 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $138 | $23.09 | +497.66% | 8 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $1.58 | +406.33% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $380 | $274.71 | +38.33% | 23 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $216 → $219 | $142.73 | +53.44% | 15 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $12 | $2.75 | +336.36% | 6 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 | $4.26 | +322.54% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $0.86 | +1,063.74% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $95 | $59.07 | +60.83% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $3.91 | +539.39% | 1 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $72 → $75 | $61.11 | +22.73% | 3 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $1.47 | +512.24% | 4 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | n/a | $8.08 | - | 6 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,200 → $500 | $1.82 | +27,372.53% | 4 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $25 → $21 | $7.61 | +175.95% | 9 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.51 | - | 2 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $84 | $16.77 | +400.89% | 1 | Mar 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.06 | - | 3 | Jul 11, 2017 |
Bicycle Therapeutics
Aug 11, 2025
Maintains: Outperform
Price Target: $48 → $44
Current: $6.91
Upside: +536.76%
Mind Medicine (MindMed)
Aug 4, 2025
Reinstates: Outperform
Price Target: $25
Current: $9.57
Upside: +161.23%
Atai Life Sciences
Jul 29, 2025
Initiates: Outperform
Price Target: $14
Current: $4.61
Upside: +203.69%
Praxis Precision Medicines
Jul 8, 2025
Maintains: Outperform
Price Target: $97 → $115
Current: $44.03
Upside: +161.19%
ACADIA Pharmaceuticals
Jun 26, 2025
Maintains: Perform
Price Target: $19 → $22
Current: $24.20
Upside: -9.09%
Prothena Corporation
May 27, 2025
Downgrades: Perform
Price Target: n/a
Current: $8.07
Upside: -
Tvardi Therapeutics
May 21, 2025
Initiates: Outperform
Price Target: $65
Current: $39.04
Upside: +66.50%
Jasper Therapeutics
May 15, 2025
Maintains: Outperform
Price Target: $80 → $65
Current: $2.34
Upside: +2,677.78%
Inovio Pharmaceuticals
May 14, 2025
Maintains: Outperform
Price Target: $15 → $13
Current: $2.18
Upside: +496.33%
Revolution Medicines
May 8, 2025
Maintains: Outperform
Price Target: $70 → $75
Current: $43.81
Upside: +71.19%
May 7, 2025
Maintains: Outperform
Price Target: $25 → $21
Current: $8.07
Upside: +160.22%
Mar 14, 2025
Upgrades: Outperform
Price Target: $90
Current: $51.06
Upside: +76.28%
Mar 3, 2025
Maintains: Outperform
Price Target: $50 → $42
Current: $13.06
Upside: +221.59%
Jan 24, 2025
Downgrades: Perform
Price Target: $41 → $33
Current: $40.44
Upside: -18.40%
Jan 13, 2025
Maintains: Outperform
Price Target: $60 → $40
Current: $12.41
Upside: +222.32%
Dec 11, 2024
Maintains: Outperform
Price Target: $80 → $20
Current: $1.79
Upside: +1,017.32%
Dec 6, 2024
Initiates: Outperform
Price Target: $30
Current: $6.15
Upside: +387.80%
Dec 4, 2024
Maintains: Outperform
Price Target: $17 → $20
Current: $7.40
Upside: +170.27%
Oct 31, 2024
Maintains: Outperform
Price Target: $270 → $255
Current: $144.87
Upside: +76.02%
Oct 30, 2024
Maintains: Outperform
Price Target: $81 → $82
Current: $84.80
Upside: -3.30%
Oct 23, 2024
Maintains: Outperform
Price Target: $375 → $350
Current: $417.74
Upside: -16.22%
Oct 17, 2024
Maintains: Outperform
Price Target: $9 → $10
Current: $2.86
Upside: +249.55%
Sep 25, 2024
Reiterates: Outperform
Price Target: $138
Current: $23.09
Upside: +497.66%
Aug 14, 2024
Assumes: Outperform
Price Target: $8
Current: $1.58
Upside: +406.33%
Aug 7, 2024
Maintains: Outperform
Price Target: $380
Current: $274.71
Upside: +38.33%
Aug 2, 2024
Maintains: Outperform
Price Target: $216 → $219
Current: $142.73
Upside: +53.44%
Jun 18, 2024
Maintains: Perform
Price Target: $12
Current: $2.75
Upside: +336.36%
May 15, 2024
Maintains: Outperform
Price Target: $18
Current: $4.26
Upside: +322.54%
May 15, 2024
Maintains: Outperform
Price Target: $10
Current: $0.86
Upside: +1,063.74%
May 10, 2024
Maintains: Outperform
Price Target: $102 → $95
Current: $59.07
Upside: +60.83%
Apr 12, 2024
Initiates: Outperform
Price Target: $25
Current: $3.91
Upside: +539.39%
Apr 9, 2024
Maintains: Outperform
Price Target: $72 → $75
Current: $61.11
Upside: +22.73%
Mar 27, 2024
Maintains: Outperform
Price Target: $9
Current: $1.47
Upside: +512.24%
Mar 5, 2024
Maintains: Perform
Price Target: n/a
Current: $8.08
Upside: -
Nov 30, 2023
Maintains: Outperform
Price Target: $1,200 → $500
Current: $1.82
Upside: +27,372.53%
Nov 22, 2023
Maintains: Perform
Price Target: $25 → $21
Current: $7.61
Upside: +175.95%
Oct 13, 2022
Downgrades: Perform
Price Target: n/a
Current: $1.51
Upside: -
Mar 20, 2018
Maintains: Outperform
Price Target: $70 → $84
Current: $16.77
Upside: +400.89%
Jul 11, 2017
Upgrades: Outperform
Price Target: n/a
Current: $1.06
Upside: -